Many treatments are now available that have been designed to specifically target HER2-positive breast cancer cells. These treatments have led to better outcomes for many individuals with this breast cancer subtype.
About 20 percent of people with breast cancer have HER2-positive tumors.
Read more details about the HER2 gene and breast cancer prognosis.
Breast cancer treatments are often given in stages. These stages are described using specific terms:
At various points during breast cancer treatment, your doctor may have you repeat HER2 testing. Results can help show whether the cancer is responding to treatment.
Read more about HER2 tests and diagnosis.
If you have early-stage breast cancer (cancer that has not yet spread throughout the body), the goal of treatment will most likely be to eliminate the entire breast tumor. If your cancer is metastatic (has spread to other areas), you may also receive treatments to get rid of these metastases. In cases of advanced breast cancer, however, the treatment goal may be different. You may receive treatments that aim to make the tumor grow more slowly or lessen your cancer symptoms.
The breast cancer treatment plan that is best for you will likely be very different from the treatment plan for someone else. Several considerations go into deciding which cancer treatment plan is a good fit for your needs, including:
People with HER2-positive breast cancer often begin treatment by receiving targeted therapy. Medications in this category are often given as both neoadjuvant and adjuvant treatments. Targeted therapies can specifically recognize and kill HER2-positive breast cancer cells.
The immune system makes proteins called antibodies to fight harmful things like viruses and cancer. Each antibody can recognize and attach to a specific substance, such as a particular protein or cell, and signal to the rest of the immune system to attack that target.
Antibodies can be manufactured in a laboratory and designed to attack targets on cancer cells. When antibodies are manufactured, they are called monoclonal antibodies. Researchers have designed several anti-HER2 monoclonal antibodies that can recognize and attack the HER2 protein.
Trastuzumab (Herceptin) was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to treat HER2-positive breast cancer. In the following years, the antibody pertuzumab (Perjeta) was also approved. The more recently approved trastuzumab-dkst (Ogivri), a biosimilar of Herceptin, is also available.
You can also take Herceptin and Perjeta together. This combination may make it more likely that all traces of cancer are removed from your body. Additionally, breast cancer cells may sometimes become resistant to one monoclonal antibody, so it can be helpful to use a combination.
Monoclonal antibodies are often given intravenously (IV) — medication is injected directly into your veins. Each dose of a monoclonal antibody may take between 30 minutes and 90 minutes. You’ll need to go to a hospital or clinic to receive an IV infusion.
More recently, researchers have developed other forms of monoclonal antibodies that can be given subcutaneously (through an injection into the fatty tissue underneath the layer of skin). This only takes a few minutes, and you may be able to have it done at your doctor’s office. This medication is called Phesgo and is a combination of trastuzumab, pertuzumab, and hyaluronidase. Because injections don’t take as long, studies have found that 85 percent of people receiving Phesgo prefer this medication over IV drugs.
HER2 belongs to a family of proteins called kinases. Kinase inhibitors are targeted drugs that can stop kinase proteins from doing their jobs. Drugs in this category that may be used to treat HER2-positive breast cancer include neratinib (Nerlynx), tucatinib (Tukysa), and lapatinib (Tykerb).
Kinase inhibitors are most often used to treat later-stage cancer or as a second-line treatment for earlier-stage tumors. These drugs usually come in the form of a pill that you take by mouth.
An antibody-drug conjugate (ADC) is a combination of targeted therapy and chemotherapy. ADCs contain a monoclonal antibody that helps the drug find cells that have the HER2 protein. The chemotherapy part of the drug then kills the cancer cell. ADC medications that may be given to people with HER2-positive breast cancer include TDM-1 or ado-trastuzumab emtansine (Kadcyla) and fam-trastuzumab deruxtecan-nxki (Enhertu).
Your doctor may prescribe an ADC as a second-line treatment for early-stage breast cancer or as a therapy for metastatic breast cancer. ADCs are usually delivered intravenously.
There are several types of surgery you may receive throughout breast cancer treatment. During a lumpectomy, the tumor and a small part of the surrounding breast are removed. In a mastectomy, the entire breast is removed. Either of these surgeries may later be followed by reconstructive surgery to help repair the breast.
People with breast cancer may also receive surgery to remove the lymph nodes — small structures that help filter harmful substances out of the body. By looking more closely at the lymph nodes, your doctor can determine whether cancer cells have begun to spread beyond the breast.
Surgery aims to remove as much of the tumor as possible from the breast. However, sometimes cancer cells remain behind in the breast or other areas of the body. Adjuvant (additional) treatments may help get rid of these remaining cells.
Radiation therapy uses beams of energy, such as X-rays, that can damage cancer cells. This treatment can help reduce the chance that a tumor comes back. For people with HER2-positive breast cancer, the combination of targeted therapy, surgery, and radiation often works well to remove the cancer and keep it from coming back.
Individuals with HER2-positive breast cancer may receive chemotherapy treatments, also referred to as chemo. Although targeted therapies are designed to recognize specific types of cancer cells, chemotherapy is a type of drug that is intended to kill any type of cancer cell.
If you have HER2-positive breast cancer, you may receive chemotherapy medication along with targeted therapy. For example, you may take the chemotherapy drug capecitabine (Xeloda) along with kinase inhibitors to treat advanced cancer or as a second-line therapy. Chemotherapy and HER2-targeted therapy drugs are sometimes given together in regimens such as:
HER2 is just one of several genetic changes a breast cancer cell may have. Breast tumors also may contain estrogen receptor (ER) or progesterone receptor (PR) proteins. ER and PR are types of hormone receptors. Cancer cells that have either of these proteins use hormones (chemicals in the body that act as messengers) in order to grow. Hormone therapy (also known as endocrine therapy) can block these hormones, starving the cancer cells and making it difficult for them to grow.
If you have breast cancer that is both HER2-positive and hormone receptor-positive (has either ER or PR), then you may receive both targeted therapies and hormone therapies. Hormone therapy medications include tamoxifen (Soltamox) and aromatase inhibitors. Hormone therapy may be given before or after surgery, alone, or with other treatments. This type of medication may be taken for five to 10 years.
New types of treatment for HER2-positive breast cancer are continuously being studied in oncology clinical trials. If you’d like to know about other possible treatment options, ask your oncologist about participating in a cancer research study. Clinical trials for breast cancer may offer access to treatments that are not widely available. Treatment provided in clinical trials may be free or lower in cost.
Some people may worry they’ll receive a placebo (sugar pill) during a clinical trial. In clinical studies for cancer, you will at minimum receive the standard-of-care effective treatment for your cancer type. If there is a chance you might receive a placebo, you’ll be informed of this possibility.
Shared decision-making is a process by which you and your doctor work together to decide on the best treatment plan for you. Your role in shared decision-making is to share your goals for treatment as well as your concerns and personal values. You can also ask questions about anything you don’t understand. Your doctor’s role is to consider your preferences and help you learn more about your condition and treatment options. Your doctor will answer questions and help you weigh the potential risks and benefits of each option. Together, you will decide on the best cancer treatment plan for you. Shared decision-making is considered vital to high-quality cancer care, and it has been shown to improve patient satisfaction.
After you and your doctor decide on a plan for the treatment of breast cancer, it is important to follow your doctor’s directions. Keep taking the medication exactly as directed, for as long as directed, even if you feel better. If you don’t follow your treatment plan, or if you stop taking medication too soon, you may experience some negative effects:
If you experience difficulty sticking to your treatment plan for any reason, talk to your doctor before making any changes. They may be able to help you manage side effects or overcome other problems.
MyBCTeam is the social network for people with breast cancer and their loved ones. On MyBCTeam, more than 61,000 members come together to ask questions, give advice, and share their stories with others who understand life with breast cancer.
Have you begun treatment for your HER2-positive breast cancer? Share your experience in the comments below, or start a conversation by posting on your Activities page.